Oncolys BioPharma Inc.

4588

JP3202170001

Pharmaceuticals

Delayed Japan Exchange Other stock markets 07:00:00 14/06/2024 BST			5-day change	1st Jan Change
698 ^JPY	0.00%		+3.71%	+23.10%

06-14	Oncolys BioPharma Inc. announced that it expects to receive ¥2.2 million in funding	CI
06-03	Medigen Biotechnology Corp. and Oncolys BioPharma Enroll First Participant in Investigator-Initiated Phase II Clinical Trial	CI

Oncolys BioPharma Inc. Provides Earnings Guidance for the Year Ending December 2021

November 05, 2021 at 06:00 am

Oncolys BioPharma Inc. provided earnings guidance for the year ending December 2021. For the year ending December 2021, the company expects net sales in the range of JPY 700 million to JPY 350 million, operating loss in the range of JPY 1,650 million to JPY 2,000 million, loss in the range of JPY 1,650 million to JPY 2,000 million, and basic loss per share in the range of JPY 112.69 to JPY 136.59.

Latest news about Oncolys BioPharma Inc.

Oncolys BioPharma Inc. announced that it expects to receive ¥2.2 million in funding	06-13	CI
Medigen Biotechnology Corp. and Oncolys BioPharma Enroll First Participant in Investigator-Initiated Phase II Clinical Trial	06-03	CI
Oncolys BioPharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-09	CI
Medigen Biotechnology Corp. Announces Signing of the Sales Cooperation Agreement for the New Drug OBP-301 in Japan	02-07	CI
Oncolys Biopharma Inc. Announces the Investigator-Initiated Phase 2 Clinical Trial Agreement with Weill Cornell Medicine	12-19	CI
Oncolys Biopharma Inc. Provides Update on Phase II Study of Telomelysin (OBP-301) in Combination with Pembrolizumab in Gastroesophageal Adenocarcinoma	11-07	CI
Oncolys Biopharma Announces Enrollment of First Expansion Cohort Patient in Phase I Clinical Trial for Telomelysin (OBP-301)-Chemoradiation Combination Therapy	11-02	CI
Oncolys BioPharma Inc. Announces Achievement of Primary Endpoint for Efficacy in the Phase2 Clinical Trial for Telomelysin-Radiation Combination Therapy	16/10/23	CI
Oncolys Biopharma Announces Meeting of Safety Endpoint in the Initial Safety Cohort of the Phase I Clinical Trial for Telomelysin?? in Combination Therapy	10/08/23	CI
Oncolys BioPharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	04/08/23	CI
Oncolys Biopharma Partner Enrolls First Patient in Phase IIa Study of Aicardi-Goutières Syndrome Drug	26/07/23	MT
Oncolys Biopharma Inc. Announces Enrollment of First Patient in Phase Iia Study for Obp-601 in Patients with Aicardi-Goutieres Syndrome	25/07/23	CI
Oncolys BioPharma Inc. announced that it has received ¥21.106 million in funding from SMBC Nikko Securities Inc., Investment Arm	23/07/23	CI
Oncolys BioPharma Inc. announced that it expects to receive ¥21.106 million in funding from SMBC Nikko Securities Inc., Investment Arm	06/07/23	CI
Oncolys BioPharma Announces Results from an Investigator-Initiated Phase II Clinical Trial for Telomelysin™? (OBP-301) in Combination with Pembrolizumab in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma	06/06/23	CI
Oncolys BioPharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Oncolys BioPharma Inc. Announces Completion of Enrollment in Phase IIa Clinical Trial of OBP-601 (censavudine, TPN-101) in Patients with Amyotrophic Lateral Sclerosis	07/03/23	CI
Oncolys BioPharma Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	04/11/22	CI
Oncolys Biopharma Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2022	04/11/22	CI
Oncolys BioPharma Inc.(TSE:4588) dropped from S&P Global BMI Index	19/09/22	CI
Oncolys Biopharma's Drug Licensee Closes Clinical Trial Enrollment for Progressive Brain Disorder Treatment	18/08/22	MT
Oncolys BioPharma Inc. Announces Completion of Enrollment in Phase IIa Clinical Trial of OBP-601 (Censavudine, TPN-101) in Patients with Progressive Supranuclear Pals	17/08/22	CI
Oncolys BioPharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	05/08/22	CI
Oncolys BioPharma Inc. Provides Earning Guidance for the Year Ending December 31, 2022	05/08/22	CI
Oncolys BioPharma Inc. Provides Earning Guidance for the Year Ending December 31, 2022	13/05/22	CI

Chart Oncolys BioPharma Inc.

Duration

Period

More charts

Company Profile

Oncolys BioPharma Inc. is a biopharmaceutical company. The Company operates in two business segments. Pharmaceutical business segment is engaged in the research, development, manufacture and marketing of pharmaceuticals. Diagnostic reagents business segment is engaged in the research, development, manufacture and marketing of diagnostic reagents and equipment, as well as the provision of inspection service. The Company's main pipeline includes OBP-301 (Telomelysin), an oncolytic virus; OBP-801, an epigenetic anticancer drug and OBP-601 for the treatment of human immunodeficiency virus (HIV) infection, among others.

Sector

Pharmaceuticals

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ONCOLYS BIOPHARMA INC.	+23.10%	92.59M
CSL LIMITED	+0.95%	92.38B
SAMSUNG BIOLOGICS CO.,LTD.	-3.03%	37.9B
BIOGEN INC.	-10.46%	33.73B
UCB	+74.71%	27.98B
BIOMARIN PHARMACEUTICAL INC.	-13.39%	15.86B
INCYTE CORPORATION	-1.08%	13.97B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.15%	11.67B
ALTEOGEN INC.	+169.04%	10.17B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-50.19%	10.04B

Biopharmaceuticals